Mesoblast Limited
(ASX:MSB) has received regulatory clearance to start Phase 2 Clinical Trials on patients with active rheumatoid arthritis.
The US Food and Drug Administration (FDA) will now allow the regenerative medicine company to begin Phase 2 clinical trials of Mesenchymal Precursor Cells (MPCs).
The randomized, double-blind placebo-controlled trial is expected to start in the second quarter of this year.
Mesoblast’s chief says the company believes the broad immuneomodulatory effects of its Mesenchymal Precursor Cells could provide a tangible benefit to patients with debilitating autoimmune diseases, including rheumatoid arthritis.
Mesoblast booked a net loss of $71.1 million in the 2012 financial year.
